Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
PureTech, Novartis create resTORbio
by Ann M. Thayer
April 3, 2017
| A version of this story appeared in
Volume 95, Issue 14
PureTech Health, an R&D and venture investment firm, has licensed two clinical-stage drug programs from Novartis and will create a subsidiary called resTORbio to further develop them. PureTech is putting about $15 million toward the effort in exchange for a 58% ownership stake. Novartis will also get an interest in resTORbio and be eligible for milestone payments and royalties. The drug candidates target inhibition of the mechanistic target of rapamycin complex 1 pathway in age-related immune conditions.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter